Inify Laboratories AB - Director's Dealing 2026

Correction: Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, 30 January 2026, Reference is made to the stock exchange

announcement made by Inify Laboratories AB (publ.) (the "Company") on 27 January

2026 regarding allocation of new shares to primary insiders in the repair issue

announced by the Company on 9 December 2025 (the "Repair Issue").

The number of shares allocated to board member Martin Ingvar was incorrectly

stated as 67,132 in the announcement of 27 January 2026. The correct number of

shares allocated to Ingvar in the Repair Issue is 67,372. Consequently, Ingvar

will, subject to the completion of the Repair Issue, own 283,435 shares in the

Company. A corrected notification form for Ingvar is attached hereto.

For further information, please contact CEO, Fredrik Palm,

[email protected], or visit https://www.inify.com.

This information is subject to the disclosure requirements in the EU Market

Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian

Securities Trading Act.

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103

-MERK) under the ticker

INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)

AI assistant